Amgen Inc. (AMGN) drops sharply after BMO Capital cut its rating from Outperform to Market Perform. The move comes despite solid earnings momentum, with investors weighing valuation, biosimilar pressure, and growth from Repatha and Tezspire.
Amgen Inc. (AMGN) drops 8.0% after BMO Capital downgraded the stock from Outperform to Market Perform, triggering a rating-driven selloff in morning trading. The decline reflects profit-taking and valuation concerns more than a clear business setback, since Amgen still has a Q2 EPS beat, an eight-quarter earnings streak, and pipeline support from Repatha and Tezspire. For investors, the move signals that execution must keep pace with a premium valuation and biosimilar pressure.
Amgen Inc. (AMGN) drops 8.04% to $402.07 in morning trading on Sept. 8, 2026, marking a sharp reversal for one of biotech's largest names. The clearest stock-specific catalyst is a same-day BMO Capital downgrade from Outperform to Market Perform, although the trading data does not support the claim that volume is running above average.
Key Takeaways
AMGN traded at $402.07 at 10:04 ET, down 8.04% from the prior close.
BMO Capital downgraded Amgen from Outperform to Market Perform at 8:49 UTC on Sept. 8.
Relative volume stood at 0.4x the 200-day average, so the tape does not confirm an above-average participation surge.
Amgen's fundamentals remain supported by a Q2 EPS beat, an 8-for-8 earnings beat streak, and growth products such as Repatha and Tezspire.
The practical investor response is to separate a rating-driven selloff from a change in the business, rather than treating an 8% decline as an automatic bargain.
The strongest named catalyst is BMO Capital's Sept. 8 rating change. The firm moved AMGN from Outperform to Market Perform, a direct shift from a bullish view to a neutral one. The timing matters because the downgrade arrived before the regular session and preceded the $402.07 price print at 10:04 ET.
That action gives investors a concrete explanation for the sudden pressure. It also fits the stock's recent run. Zacks reported on Sept. 3 that AMGN had risen 8.6% since its latest earnings report. A downgrade after that advance can encourage profit-taking, especially when the shares sit near the upper end of their recent range.
However, the volume evidence needs careful handling. Relative volume was 0.4x the 200-day average in the stock data. That is below average, not above it. The price decline is therefore significant, but the available volume measure does not show broad, unusually heavy participation. A thinly traded morning move can still be painful, yet it does not carry the same confirmation as a selloff accompanied by several times normal volume.
Amgen Earnings Strength Conflicts With the Stock's Weakness
Amgen's latest earnings record does not point to an immediate operating breakdown. For Q2 2026, reported EPS was $6.29 versus a $5.60 estimate, producing a 12.3% surprise. The company has beaten EPS estimates in each of the last eight quarters. That record gives the fundamental case a stronger base than the morning share-price action suggests.
The valuation still leaves room for disappointment. AMGN carries a P/E ratio of 27.174 and a market capitalization of $217B. Its dividend yield is 2.21%, supported by a quarterly dividend of $2.52 announced on July 30. Those figures provide income and scale, but they do not make the stock automatically cheap after a decline.
Analyst views also remain split rather than uniformly bearish. The current rating consensus is Buy, with 23 Buy ratings, 14 Holds, and three Sells. The consensus price target is $390.89, below the $402.07 trading price, while the target range spans $230 to $460. That wide spread signals meaningful disagreement about how much value investors should assign to Amgen's pipeline and commercial portfolio.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Repatha, Tezspire and Biosimilar Pressure Shape AMGN's Outlook
Amgen's competitive position rests on a diversified portfolio rather than one medicine. Repatha remains a major cardiovascular growth asset. On Aug. 31, Amgen said Repatha reduced the risk of death in high-risk patients without a prior heart attack or stroke. That outcome strengthens the product's long-term commercial narrative.
Tezspire adds another growth avenue. On Aug. 27, Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Uplizna and oncology products also contributed to the growth story cited after Q2. These developments help offset pressure on older products.
The offset is important because Amgen faces biosimilar erosion in Prolia and XGEVA. Mature brands such as Otezla and Enbrel also face slower growth or erosion. In plain English, Amgen has a strong engine, but several older components are losing power. The stock's valuation depends on newer products replacing that lost momentum.
The most disciplined approach is to treat today's drop as a rating and positioning event first, not as proof that Amgen's earnings engine has failed. The Q2 EPS beat, eight-quarter beat streak, positive Repatha update, and Tezspire trial result all support that distinction.
At the same time, the 27.174 P/E ratio demands execution. Investors considering an entry should weigh the $402.07 price against the $390.89 consensus target, the 2.21% dividend yield, and the need for Repatha, Tezspire, Uplizna, and oncology products to overcome biosimilar pressure. The Sept. 10 Wells Fargo Healthcare Conference is the next dated Amgen investor event, giving the market a defined near-term point for company updates.
The key risk is not simply one analyst downgrade. It is the possibility that valuation remains high while growth products take longer to offset mature-brand erosion. The key opportunity is that the selloff has occurred alongside strong recent earnings and favorable pipeline news. That tension makes position size and entry price more important than headline emotion.
Bottom Line for Amgen Stock
AMGN drops sharply today, with BMO Capital's downgrade providing the clearest specific catalyst. Yet the 0.4x relative-volume reading and Amgen's 12.3% Q2 EPS beat argue against calling this a confirmed fundamental breakdown.
Investors should focus on whether Amgen's newer growth assets can keep replacing revenue pressure from mature products and biosimilars. The stock may offer a better entry after the decline, but the 27.174 P/E ratio means the business still has to deliver.
AMGN is down today mainly because BMO Capital downgraded Amgen from Outperform to Market Perform before the market opened. The selloff looks rating-driven rather than caused by a new earnings miss or a major business setback.
+Should I buy AMGN stock now?
Not automatically. The drop may improve the entry point, but Amgen still trades at a relatively rich valuation and needs continued growth from newer products to offset biosimilar pressure.
+Was there bad earnings news behind Amgen's drop?
No, the latest earnings data was actually strong, with Amgen beating Q2 EPS estimates and extending its streak of quarterly beats. Today's weakness is tied more to the analyst downgrade and market positioning than to a fresh earnings disappointment.
+Is this AMGN selloff confirmed by heavy trading volume?
No. The available data shows relative volume at 0.4x the 200-day average, which is below normal. That means the move is sharp, but it is not backed by unusually heavy participation.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on AMGN?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
